Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Jun 05, 2018 7:58pm

136 Views

Post# 28129360

RE:RE:RE:RE:RE:RE:RE:RE:CIBC dropping coverage on TH and others-Analyst has departed

So speculating on top of your speculation, Not indicative M&A.

palinc2000 wrote:

palinc2000 wrote:

SPCEO1 wrote:

palinc2000 wrote: Speculating that he might end up at Thera as an officer to help with US listing

https://ca.linkedin.com/in/prakashgowd

He was the first analyts from a major firm to cover TH .......maybe he fell in love with the company

He is a very good analyst and I think the company liked him a lot too. When I e-mailed the company if they knew where he was headed the response was "no news". So, that may mean they had not heard or it may have been they were not ready to say anything yet about him joining TH. I assume it would be in a Investor relations role, or at least that would be part of his job. Now, He probably does not have a lot of experience talking to US investors given the Canadian focus of his coverage, so he would not bring a ton of insight there, but he is a smart guy and does have some experience with US investors.

I have no idea but that is a fun thing to speculate about. The company is getting bigger in terms of amrket cap and I am sure Philippe's time is increasingly being chewed up by investors. So, having an IR person is clearly justified. Maybe youa re right. I would have no problem with that.

This is how he describes himself on Linkedin

25 years of commercial/corporate development and capital markets experience in the healthcare, and bio-pharma industries:
Healthcare & Biotech Investment Research & Analysis
Strategic Business Analysis & Planning, Pharma Marketing, New Product Development
Corporate Strategy & Business Development
Board of Directors (Chartered Director

Principal

Life Science Consulting

2009 – 2015 (6 years)Oakville

Selected Roles:
* Vice President, Corporate Development, Axcelon Biopolymers
* Managing Director, Healthcare Investment Banking, Echelon Wealth Partners
* CEO, InDanio Bioscience , and Strategic Advisor, MaRS Discovery District

Corporate Director & Chair of the Audit Committee

Isotechnika Pharma Inc.

December 2010 – November 2013 (3 years)Edmonton, Canada Area

Director & Senior Healthcare & Biotech Investment Research Analyst

National Bank Financial & Canaccord Capital

2001 – 2008 (7 years)

Pharmaceutical Marketing, Brand Management, Market Research & New Product Development

GlaxoSmithKline & PSL Consulting Group

1992 – 2001 (9 years)